Cargando…

Incidence of AQP4-IgG seropositive neuromyelitis optica spectrum disorders in the Netherlands: About one in a million

Neuromyelitis optica (NMO) is a rare autoimmune disease affecting the optic nerves and spinal cord. In the majority of NMO patients anti-aquaporin-4 antibodies (AQP4-IgG) are detected. Here we assessed a nationwide incidence of AQP4-IgG-seropositive NMO spectrum disorders (NMOSD) in the Netherlands...

Descripción completa

Detalles Bibliográficos
Autores principales:	Daniëlle van Pelt, E, Wong, Yu Yi M, Ketelslegers, Immy A, Siepman, Dorine AM, Hamann, Dörte, Hintzen, Rogier Q
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2016
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433331/ https://www.ncbi.nlm.nih.gov/pubmed/28607712 http://dx.doi.org/10.1177/2055217315625652

Ejemplares similares

Altered fovea in AQP4-IgG–seropositive neuromyelitis optica spectrum disorders
por: Motamedi, Seyedamirhosein, et al.
Publicado: (2020)

Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica
por: Duan, Tianjiao, et al.
Publicado: (2018)

CD55 upregulation in astrocytes by statins as potential therapy for AQP4-IgG seropositive neuromyelitis optica
por: Tradtrantip, Lukmanee, et al.
Publicado: (2019)

Cytoprotective IgG antibodies in sera from a subset of patients with AQP4-IgG seropositive neuromyelitis optica spectrum disorder
por: Tradtrantip, Lukmanee, et al.
Publicado: (2021)

A multi-facet comparative analysis of neuromyelitis optica spectrum disorders in patients with seropositive and seronegative AQP4-IgG
por: Wang, Xiaojuan, et al.
Publicado: (2018)

Complement-independent bystander injury in AQP4-IgG seropositive neuromyelitis optica produced by antibody-dependent cellular cytotoxicity
por: Duan, Tianjiao, et al.
Publicado: (2019)

Astrocytic outer retinal layer thinning is not a feature in AQP4-IgG seropositive neuromyelitis optica spectrum disorders
por: Lu, Angelo, et al.
Publicado: (2022)

AQP4-IgG autoimmunity in Japan and Germany: Differences in clinical profiles and prognosis in seropositive neuromyelitis optica spectrum disorders
por: Asseyer, Susanna, et al.
Publicado: (2021)

Paraneoplastic AQP4-IgG–Seropositive Neuromyelitis Optica Spectrum Disorder Associated With Teratoma: A Case Report and Literature Review
por: Ikeguchi, Ryotaro, et al.
Publicado: (2021)

Differences in Advanced Magnetic Resonance Imaging in MOG-IgG and AQP4-IgG Seropositive Neuromyelitis Optica Spectrum Disorders: A Comparative Study
por: Schmidt, Felix A., et al.
Publicado: (2020)

Free-water diffusion tensor imaging detects occult periependymal abnormality in the AQP4-IgG-seropositive neuromyelitis optica spectrum disorder
por: Kim, Minchul, et al.
Publicado: (2022)

Optical coherence tomography angiography helps distinguish multiple sclerosis from AQP4‐IgG‐seropositive neuromyelitis optica spectrum disorder
por: Liu, Chunxin, et al.
Publicado: (2021)

Long-term Efficacy of Satralizumab in AQP4-IgG–Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar
por: Kleiter, Ingo, et al.
Publicado: (2022)

Pain in AQP4-IgG-positive and MOG-IgG-positive neuromyelitis optica spectrum disorders
por: Asseyer, Susanna, et al.
Publicado: (2018)

Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders
por: Palace, Jacqueline, et al.
Publicado: (2019)

Dramatic efficacy of ofatumumab in refractory pediatric-onset AQP4-IgG neuromyelitis optica spectrum disorder
por: Maillart, Elisabeth, et al.
Publicado: (2020)

Difference in the Source of Anti-AQP4-IgG and Anti-MOG-IgG Antibodies in CSF in Patients With Neuromyelitis Optica Spectrum Disorder
por: Akaishi, Tetsuya, et al.
Publicado: (2021)

Safety and efficacy of plasma exchange treatment in children with AQP4-IgG positive neuromyelitis optica spectrum disorder
por: Li, Zhichao, et al.
Publicado: (2023)

No association of AQP4 polymorphisms with neuromyelitis optica and multiple sclerosis
por: Yang, Ting-Ting, et al.
Publicado: (2016)

Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results
por: Qin, Chuan, et al.
Publicado: (2023)

Neuromyelitis optica-IgG testing in an Indian cohort with neuromyelitis optica and related demyelinating disorders: Our experience
por: Unni, Narayanan, et al.
Publicado: (2013)

HLA association in MOG-IgG– and AQP4-IgG–related disorders of the CNS in the Dutch population
por: Bruijstens, Arlette L., et al.
Publicado: (2020)

Pregnancy-Related Attack in Neuromyelitis Optica Spectrum Disorder With AQP4-IgG: A Single-Center Study and Meta-Analysis
por: Deng, Shuwen, et al.
Publicado: (2022)

Intrastriatal injection of interleukin-1 beta triggers the formation of neuromyelitis optica-like lesions in NMO-IgG seropositive rats
por: Kitic, Maja, et al.
Publicado: (2013)

Investigating paraneoplastic aquaporin‐4‐IgG‐seropositive neuromyelitis optica spectrum disorder through a data‐driven approach
por: Dinoto, Alessandro, et al.
Publicado: (2022)

NMO-IgG: A Specific Biomarker for Neuromyelitis Optica
por: Weinshenker, Brian G., et al.
Publicado: (2006)

Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder: A Cross-Sectional Study of 166 AQP4 Antibody–Seropositive Patients
por: Ayzenberg, Ilya, et al.
Publicado: (2021)

Factors influencing intravenous methylprednisolone pulse therapy in Chinese patients with isolated optic neuritis associated with AQP4 antibody-seropositive neuromyelitis optica
por: Guo, Sitong, et al.
Publicado: (2021)

AQP4ex is crucial for the anchoring of AQP4 at the astrocyte end-feet and for neuromyelitis optica antibody binding
por: Palazzo, Claudia, et al.
Publicado: (2019)

Update on biomarkers in neuromyelitis optica
por: Melamed, Esther, et al.
Publicado: (2015)

Neuromyelitis optica spectrum disorder with AQP4‐IgG presenting as area postrema syndrome and progressing to myelitis: A rare case report
por: Jagannath, Preethi, et al.
Publicado: (2023)

The evolving mystery of why skeletal muscle is spared in seropositive neuromyelitis optica
por: Verkman, Alan S., et al.
Publicado: (2018)

Magnetic resonance imaging findings in a patient with seropositive neuromyelitis optica
por: Mpateni, Siviwe S., et al.
Publicado: (2018)

SAkuraBONSAI: Protocol design of a novel, prospective study to explore clinical, imaging, and biomarker outcomes in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder receiving open-label satralizumab
por: Bennett, Jeffrey L., et al.
Publicado: (2023)

Plasmablasts as Migratory IgG-Producing Cells in the Pathogenesis of Neuromyelitis Optica
por: Chihara, Norio, et al.
Publicado: (2013)

Effects of neuromyelitis optica–IgG at the blood–brain barrier in vitro
por: Takeshita, Yukio, et al.
Publicado: (2016)

Aquaporin-4 Autoantibodies in Neuromyelitis Optica: AQP4 Isoform-Dependent Sensitivity and Specificity
por: Pisani, Francesco, et al.
Publicado: (2013)

Peripapillary hyper-reflective ovoid mass-like structures (PHOMS) in AQP4-IgG-positive neuromyelitis optica spectrum disease (NMOSD) and MOG-IgG-associated disease (MOGAD)
por: Gernert, Jonathan A., et al.
Publicado: (2022)

Fatal anti-aquaporin-4 seropositive neuromyelitis optica spectrum disorder in tuberculosis
por: Sridhar, Siddharth, et al.
Publicado: (2014)

Response to ‘The evolving mystery of why skeletal muscle is spared in seropositive neuromyelitis optica’
por: Frigeri, Antonio, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_r268tnp3iqa8558oltbprk4j4d